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Background: Although depression appears to decrease in late life, this could be due to
misattribution of depressive symptoms to physical disorders that increase in late life.
Methods: We investigated this issue by studying age differences in co-morbidity of
DSM-IV major depressive episodes (MDE) with chronic physical conditions in the
WHOWorld Mental Health (WMH) surveys, a series of community epidemiological
surveys of respondents in 10 developed countries (n552,485) and 8 developing
countries (n537,265). MDE and other mental disorders were assessed with the
Composite International Diagnostic Interview (CIDI). Organic exclusion rules were
not used to avoid inappropriate exclusion of cases with physical co-morbidity. Physical
conditions were assessed with a standard chronic conditions checklist. Results:
Twelve-month DSM-IV/CIDI MDE was significantly less prevalent among
respondents ages 651 than younger respondents in developed but not developing
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countries. Prevalence of co-morbid mental disorders generally either decreased or
remained stable with age, while co-morbidity of MDE with mental disorders
generally increased with age. Prevalence of physical conditions, in comparison,
generally increased with age, while co-morbidity of MDE with physical conditions
generally decreased with age. Depression treatment was lowest among the elderly in
developed and developing countries. Conclusions: The weakening associations
between MDE and physical conditions with increasing age argue against the
suggestion that the low estimated prevalence of MDE among the elderly is due to
increased confounding with physical disorders. Future study is needed to investigate
processes that might lead to a decreasing impact of physical illness on depression
among the elderly. Depression and Anxiety 27:351–364, 2010. r2009Wiley-Liss, Inc.
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INTRODUCTION
Community epidemiological surveys in developed
countries consistently find that current prevalence of
major depression decreases with age and is especially
low among the elderly.[1–3] A number of methodological
explanations have been proposed for this finding,
suggesting that age-related differentials in mortality,
selection out of the household population, willingness to
participate in surveys, and willingness to admit psychia-
tric problems lead to downward bias in prevalence
estimates among the elderly.[4,5] However, evidence for
these methodological interpretations is weak,[6] leading
some commentators to conclude that the prevalence of
depression is genuinely low among the elderly.[2]
An important issue in studying late-life depression is
that many physical disorders increase in old age, possibly
resulting in depression being under-estimated because it
is confused with the symptoms of physical disorders.[7] A
complicating factor is that some somatic disorders that
increase with age can induce depression,[8,9] while late-
life depression can increase risk of some physical
disorders.[10,11] In an effort to shed light on this issue,
we analyzed data on age-related changes in the associa-
tions of physical disorders with DSM-IV major depres-
sive episodes (MDE) in the World Health Organization
(WHO) World Mental Health (WMH) surveys.[12]
Parallel analyses were carried out for co-morbid DSM-
IV mental disorders. MDE was defined without either
organic exclusions or diagnostic hierarchy rules to
facilitate investigation of co-morbidity. Our primary
aims were to see whether the presumed decline in MDE
prevalence with age is associated with co-morbidity. In
studying co-morbidity, we focused on associations rather
than conditional prevalence, as data already exist on age-
related changes in prevalence[13–15] but not on age-
related changes in associations. An examination of these
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associations is of interest because we would expect them
to increase with age if the assessment of MDE is
confounded by physical disorders. As a preliminary to
these analyses, we also examined MDE prevalence by
age as well as age differences in the ratios of recent
to lifetime prevalence, age-of-onset distributions, and
persistence-severity of 12-month MDE.
METHODS
SAMPLE
Data are presented for 17 countries, 10 classified by the World
Bank developed (Belgium, France, Germany, Israel, Italy, Japan,
Netherlands, New Zealand, Spain, and United States), and 8
developing (Brazil, Colombia, India, Lebanon, Mexico, South Africa,
Ukraine, and Shenzhen in the People’s Republic of China).[16] A total
of 89,750 adults participated in the surveys 52,485 in developed and
37,265 in developing countries (Table 1). All surveys involved
nationally representative household samples except Colombia and
Mexico, which featured representative samples of urban areas.
Weights were used to adjust for differential probabilities of selection
and to match sample socio-demographic distributions with popula-
tion distributions. The weighted average response rate across surveys
was 71.8%, ranging from 45.9% in France to 98.6% in India. Other
than in Israel and South Africa, where all respondents were
administered the full interview, subsampling was used to reduce
respondent burden by dividing the interview into two parts. All
respondents completed Part I, which assessed core mental disorders.
Part II assessed additional disorders and correlates and was
administered to all Part I respondents who met criteria for any Part
I disorder plus a probability subsample of other Part I respondents.
Part II responses were weighted by the inverse of their probability of
selection to adjust for differential selection. Further details about
WMH survey methodology are presented elsewhere.[17]
MEASURES
Mental disorders. Mental disorders were assessed using the
WHO Composite International Diagnostic Interview (CIDI) Version
3.0,[18] a fully structured lay-administered interview that generates
diagnoses for commonly occurring DSM-IV mental disorders. In
addition to MDE, these disorders included other mood (dysthymic
disorder and bipolar disorder), anxiety (generalized anxiety disorder,
panic disorder, agoraphobia without panic disorder, specific phobia,
social phobia, post-traumatic stress disorder, adult separation anxiety
disorder), substance (alcohol and drug abuse with and without
dependence), and intermittent explosive disorder. Blinded clinical
reappraisal interviews using the Structured Clinical Interview for
DSM-IV (SCID)[19] with a probability subsample of WMH survey
respondents from four countries found generally good concordance
between diagnoses based on the CIDI and those based on the
SCID.[20] DSM-IV/CIDI disorders were defined without organic
exclusions and without diagnostic hierarchy rules in order to facilitate
analysis of co-morbidity. Although no comparisons were made of
differences in diagnoses with and without these exclusions, previous
WMH analyses suggest that such differences are slight.[15]
MDE course was examined using retrospectively reported data on
age-of-onset, number of lifetime episodes, and number of weeks in
episode in the past 12 months. MDE clinical severity was assessed
among 12-month cases using the Quick Inventory of Depressive
Symptomatology Self-Report (QIDS).[21] Standard QIDS cut-points
were used to define episodes as severe, moderate, mild, or not clinically
significant. Role impairment among 12-month cases was assessed using
the Sheehan Disability Scale (SDS),[22] which asks respondents to rate
how much their 12-month depression interferes with their home
management, work performance, social life, and personal relationships
on a 0–10 visual analogue scale with response anchors of none (0), mild
(1–3), moderate (4–6), severe (7–9), and very severe (10). Both the
QIDS and the SDS assessed severity for the one month in the past year
when symptoms were most severe. Respondents with 12-month MDE
were also asked to estimate the number of days out of 365 in the past
year they were totally unable to work or carry out their other usual
daily activities because of their depression.
Co-morbid physical disorders. Physical disorders were
assessed with a standard chronic conditions checklist containing 14
conditions based on the list in the US National Health Interview
Survey.[23,24] Such checklists are widely used in epidemiological
studies and yield more accurate reports than open-ended ques-
tions.[25] Good concordance has been documented between condition
reports based on such checklists and medical records.[26–28] The 14
physical conditions considered here include cardiovascular (heart
attack, hypertension, other heart disease, stroke), musculoskeletal
(arthritis/rheumatism, chronic back/neck problems), respiratory
(seasonal allergies, asthma, other chronic lung disease such as chronic
obstructive pulmonary disorder and tuberculosis), and pain (frequent/
severe headaches, other chronic pain conditions) along with cancer,
diabetes, and ulcers. Although respondents reported the presence of
each condition in their lifetime and during the past 12 months, we
focus on disorders present in the past 12 months.
Depression treatment. Respondents were asked about
treatment obtained at any time in the 12 months before interview
for problems with emotions, nerves, or substance use. We examine
treatment among respondents with 12-month DSM-IV/CIDI MDE
separately in the specialty sector (psychiatrist or other mental health
professional), general medical sector (MD or non-MD health
professional excluding mental health professionals), human services
sector (religious counselors, social workers seen in a human services
setting), and the complementary-alternative medical (CAM) sector
(e.g., self-help groups, faith healers, traditional healers).
ANALYSIS METHODS
Age differences in prevalence, course, severity, and treatment of
MDE were examined using cross-tabulations and mean comparisons.
Multiple regression analysis with both linear and logistic link functions
was used to study co-morbidity of MDE with other physical and
mental disorders. Regression equations were estimated separately in
four age groups (18–34, 35–49, 50–64, and 651) in developed and
developing countries. These equations included covariates for sex,
income, employment status (employed/self-employed, student, home-
maker, retired, and disabled/unemployed), and marital status (married,
previously married, and never married). Wald w2 tests (logistic
regressions) and F-tests (linear regressions) were used to evaluate the
significance of interactions. We also evaluated whether the conditional
prevalence of co-morbid disorders among people with MDE varies
with age. Because the data are weighted and clustered, the Taylor series
linearization method[29] implemented in the SUDAAN software
package[30] was used to estimate standard errors. Statistical significance
was evaluated using .05-level two-sided tests.
RESULTS
PREVALENCE
The estimated 12-month prevalence of MDE is 5.5%
in developed countries and 5.9% in developing
countries (Table 2). These estimates vary significantly
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across the four age groups in developed (w23 ¼ 150:2,
Po.001) but not developing (w23 ¼ 2:2, P5.52) coun-
tries. The significant association in developed countries
is due to highest prevalence in the youngest age group
(18–34; 7.0%) and lowest in the oldest age group (651;
2.6%). This pattern is statistically significant in 7 of the
10 developed countries. The exceptions are Israel, Italy,
and Spain, all with insignificant age-MDE associa-
tions (w43 ¼ 0:56:5, P5.09–.91). The association is
also insignificant in four of the seven developing
countries (Colombia, Lebanon, Mexico, South Africa;
w23 ¼ 3:06:3, P5.10–.39). In one of the other three
(Brazil), the pattern is similar to developed countries,
with highest prevalence in the youngest age group
and lowest in the oldest age group (10.9% vs.
3.9%, w23 ¼ 36:1, Po.001). An opposite pattern is
found in one other developing country (Ukraine), with
lowest prevalence among the young and highest among
the old (6.0% vs. 13.0%, w23 ¼ 21:2, Po.001). The age
trend is significant but not monotonic, in the remain-
ing developing country (India) (w23 ¼ 33:0, Po.001).
AGE-OF-ONSET, COURSE, AND SEVERITY
OF MDE
Retrospectively reported MDE age-of-onset (AOO)
varies significantly with age in both developed
(w23 ¼ 3717:2, Po.001) and developing (w23 ¼ 1596:3,
Po.001) countries, with mean AOO increasing mono-
tonically from youngest (19.1–19.3) to oldest
(46.3–40.3) age groups (Table 3). The difference
between mean age-at-interview and mean AOO of
MDE in each age group also increases consistently with
age. This is important because it is what we would
expect based on substantive processes and argues against
a methodological interpretation of the age differences,
as methodological confounding would be expected to
cause the difference between age-at-interview and AOO
to remain constant with age.[31] Mean number of
lifetime episodes of MDE among respondents with a
lifetime history also increases monotonically with age
(w23 ¼ 21:336:1, Po.001). Country-specific analyses
(not shown, but available on request) find similar age-
related patterns of onset-course in each country.
The mean self-reported duration of MDE (in weeks)
in the 12 months before interview among 12-month
cases increases monotonically from youngest to oldest
ages in both developed (25.3 vs. 31.7, F3, 2,96954.8,
P5.002) and developing (23.1 vs. 33.8, F3, 2,28953.6,
P5.013) countries. The relationship between age
and severity of 12-month MDE, however, differs both
by type of country and type of measure. Clinical
severity, as assessed by the QIDS, varies inversely with
age in developed countries (w23 ¼ 15:2, P5.002), with
the percent classified clinically severe lower in the
TABLE 2. Twelve-month prevalence of DSM-IV/CIDI MDE by country and age
Age groups
All ages 18–34 35–49 50–64 651
% (se) % (se) % (se) % (se) % (se) Age difference w23
I. Developed
Belgium 5.0 (0.5) 6.1 (1.8) 5.2 (0.9) 5.8 (1.4) 2.4 (0.7) 9.1
France 5.9 (0.6) 8.3 (1.4) 6.0 (0.9) 5.6 (1.2) 2.5 (0.8) 19.1
Germany 3.0 (0.3) 4.7 (0.8) 2.8 (0.5) 2.9 (0.7) 1.3 (0.4) 13.5
Israela 6.1 (0.4) 6.3 (0.6) 5.7 (0.7) 6.2 (0.8) 6.0 (0.9) 0.5
Italy 3.0 (0.2) 2.8 (0.4) 2.3 (0.4) 3.8 (0.6) 3.3 (0.7) 6.2
Japan 2.2 (0.4) 4.0 (1.0) 2.1 (0.6) 2.1 (0.5) 1.0 (0.4) 10.8
Netherlands 4.9 (0.5) 5.9 (1.1) 5.7 (1.2) 4.3 (0.9) 2.4 (0.7) 9.2
New Zealanda 6.6 (0.3) 9.9 (1.1) 7.6 (0.5) 5.8 (0.5) 1.8 (0.3) 138.1
Spain 4.0 (0.3) 3.6 (0.7) 3.8 (0.5) 5.4 (0.7) 3.6 (0.6) 6.5
United States 8.3 (0.3) 10.4 (0.5) 9.4 (0.5) 7.7 (0.7) 2.6 (0.4) 103.5
Combined 5.5 (0.1) 7.0 (0.3) 6.0 (0.2) 5.1 (0.2) 2.6 (0.2) 150.2
II. Developing
Brazil 10.4 (0.6) 10.9 (0.7) 11.8 (1.2) 9.1 (1.1) 3.9 (1.1) 36.1
Colombiab 6.2 (0.4) 7.6 (0.9) 5.5 (0.7) 4.8 (1.0) 5.9 (1.0) 5.3
India 4.5 (0.4) 2.2 (0.3) 6.3 (0.8) 7.9 (1.2) 5.2 (1.6) 33.0
Lebanon 5.5 (0.7) 5.2 (1.1) 6.6 (1.1) 5.8 (1.0) 3.1 (1.1) 6.1
Mexicob 4.0 (0.3) 3.7 (0.5) 3.7 (0.4) 4.6 (0.9) 5.2 (0.8) 6.3
South Africa 4.9 (0.4) 4.5 (0.6) 5.4 (0.9) 5.6 (1.0) 3.5 (1.1) 3.0
Ukraine 8.4 (0.6) 6.0 (0.7) 6.7 (0.8) 10.1 (1.1) 13.0 (1.7) 21.2
Combined 5.9 (0.2) 5.3 (0.2) 6.2 (0.3) 6.8 (0.4) 7.5 (0.8) 2.2
Significant age difference at the .05-level, two-sided test.
aThe lower end of the age range was 16 in New Zealand and 21 in Israel.
bThe upper end of the age range was 65 in Colombia and Mexico. As a result, the age groups used in these countries was 18–29, 30–44, 45–54, 551.
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651 age group (19.6%) than younger age groups
(29.6–39.7%). Clinical severity does not vary with age,
in comparison, in developing countries (w23 ¼ 3:7,
P5.296), although the proportion of 12-month cases
rating their recent MDE as causing severe role
impairment varies inversely with age in both developed
(65.3% vs. 54.8%, w23 ¼ 12:4, P5.006) and developing
(49.3% vs. 42.7%, w23 ¼ 11:4, P5.010) countries. Mean
number of days out of role in the past year due to MDE
among 12-month cases is lowest in the oldest age
group in developed countries (25.5 vs. 46.4–52.5,
F3, 2,969512.4, P5.006), but highest in the oldest age
group in developing countries (50.4 vs. 16.0–34.9,
F3, 2,2895 3.6, P5.013).
CO-MORBIDITY OF 12-MONTH MDE WITH
OTHER 12-MONTH DSM-IV DISORDERS
All 14 12-month DSM-IV disorders considered
here are significantly and positively associated with
12-month MDE in the total sample in both developed
and developing countries and in both linear and logistic
regression models. (Detailed results are not reported,
but are available on request.) There is a general
tendency for odds-ratios (ORs) of MDE with classes
of 12-month co-morbid DSM-IV/CIDI disorders (i.e.,
mood, anxiety, and substance disorders) and with
numbers of such disorders to increase with age
(Table 4). More disaggregated analyses (results not
reported, but available on request) show that ORs of
12-month MDE with co-morbid 12-month disorders
vary significantly with age for six of the 14 co-morbid
disorders in developed countries, in four of which the
OR is highest in the oldest age group (bipolar disorder,
generalized anxiety disorder, PTSD, and panic dis-
order), and for five of the 14 co-morbid disorders in
developing countries, in two of which the OR is highest
in the oldest age group (dysthymia and adult separation
anxiety disorder).
Despite the ORs generally increasing with age, the
conditional prevalence of co-morbid mental disorders
TABLE 3. Dimensions of DSM-IV/CIDI MDE lifetime onset-course and 12-month persistence-severity by age among
WMH respondents with MDE
Age groups
All ages 18–34 35–49 50–64 651
Est (se) Est (se) Est (se) Est (se) Est (se) Age difference F/w2c
I. Developed
A. Lifetime onset and course
Mean age of onset 28.9 (0.2) 19.1 (0.1) 27.6 (0.3) 35.6 (0.3) 46.3 (0.7) 3717.2
Mean number of lifetime episodes 14.8 (0.7) 11.0 (1.0) 14.3 (1.0) 18.1 (1.7) 21.9 (3.6) 21.3
(n) (7,917) (2,325) (2,764) (1,890) (938)
B. Twelve-month persistence and severity
Mean 12-month duration (in weeks) 27.0 (0.5) 25.3 (0.8) 27.2 (0.8) 28.9 (1.1) 31.7 (1.8) 4.8
Clinically severe (%)a 33.9 (1.0) 34.7 (1.7) 39.7 (1.7) 29.6 (2.3) 19.6 (2.8) 15.2
Severe role impairment (%)b 65.8 (1.3) 65.3 (2.0) 68.2 (2.2) 66.2 (3.2) 54.8 (4.7) 12.4
Mean days out of role 48.3 (1.4) 49.2 (2.2) 52.5 (2.3) 46.4 (3.5) 25.5 (4.4) 12.4
(n) (2,973) (1,079) (990) (625) (279)
II. Developing
A. Lifetime onset and course
Mean age of onset 27.2 (0.2) 19.3 (0.2) 29.1 (0.3) 38.5 (0.6) 40.3 (1.1) 1596.3
Mean number of lifetime episodes 10.9 (0.9) 5.7 (0.5) 9.7 (1.3) 13.8 (1.9) 35.3 (6.7) 36.1
(n) (4,365) (1,640) (1,455) (885) (385)
B. Twelve-month persistence and severity
Mean 12-month duration (in weeks) 26.0 (0.7) 23.1 (1.1) 25.4 (1.1) 29.2 (1.2) 33.8 (2.3) 3.6
Clinically severe (%)a 41.8 (1.2) 38.3 (1.8) 47.8 (2.5) 43.7 (2.8) 36.8 (3.5) 3.7
Severe role impairment (%)b 49.3 (1.6) 49.3 (2.8) 53.1 (2.6) 46.4 (2.7) 42.7 (3.7) 11.4
Mean days out of role 25.3 (2.1) 16.0 (2.6) 25.0 (3.5) 34.9 (5.4) 50.4 (6.3) 3.6
(n) (2,293) (898) (732) (455) (208)
Significant age difference at the .05 level, two-sided test.
aThe percent of cases whose depression was classified either severe or very severe on the self-report version of the Quick Inventory of Depressive
Symptomatology.[21]
bThe percent of cases whose depression-related role impairment was classified either severe or very severe on any dimension of the Sheehan
Disability Scales.[22]
cSignificance was evaluated with an F test for the means (age of onset, mean number of lifetime episodes, mean duration) and a w2 test for the
proportions (the percent of cases classified clinically mild, clinically severe, and having severe role impairment). The w2 tests all have 3 degrees of
freedom, while the F tests have 3 and 7,913 degrees of freedom in developed countries and 3 and 4,361 in developing countries for lifetime means
and 3 and 2,969 degrees of freedom in developed countries and 2,289 degrees of freedom in developing countries for 12-month means.
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among people with 12-month MDE generally either
remains stable or decreases with age. These differences
between logistic and linear regression results are due to
a methodological fact: that ORs can be large even when
the proportions of people with a co-morbid disorder
are small. It is consequently useful to examine patterns
of co-morbidity based not only on logistic regression
equations but also on linear regression equations. This
analysis (detailed results are not shown, but are
available on request) showed that even though the
ORs of MDE with co-morbid mental disorders
generally increase with age, age-related differences in
prevalence of these disorders between respondents with
vs. without MDE are much less consistent. Linear
regression coefficients of MDE with co-morbid mental
disorders are predominantly lowest among the oldest
respondents (9 of 14 disorders, four of them significant:
dysthymia, specific phobia, alcohol abuse with depen-
dence, drug abuse with dependence) in developed
countries, but as likely to be highest (6 of 14 disorders,
two of them significant: bipolar disorder, adult separa-
tion anxiety disorder) as lowest (5 of the other 14
disorders, two of them significant: specific phobia, drug
abuse) among the oldest respondents in developing
countries.
CO-MORBIDITY OF 12-MONTH MDE WITH
12-MONTH CHRONIC PHYSICAL
DISORDERS
As with mental disorders, all 14 physical conditions
are positively related to MDE in linear models in both
developed (12 statistically significant) and developing
(all 14 significant) countries. (Detailed results are not
presented, but are available on request.) Eleven of the
14 are also positively related to MDE in logistic models
in developed countries (eight significant) and 13 of the
14 in developing countries (12 significant). A similar
pattern exists for both aggregated classes and numbers
of co-morbid physical conditions, where 18 of 22
associations are positive (17 statistically significant)
(Table 5). However, unlike the situation with co-
morbid mental disorders, where ORs generally increase
with age, ORs of MDE with physical conditions
generally are unrelated to age. The differences that
do exist usually reflect the OR being lowest rather than
highest in the oldest age groups.
A similar pattern can be seen in the linear regression
results in developed countries (results not shown, but
available on request), where prevalence differences in
co-morbid physical conditions between people with vs.
without MDE consistently (13 of 14 conditions)
decrease with age (8 statistically significant). This
pattern is less consistent in developing countries,
where the prevalence difference is lower with increas-
ing age for only five conditions and none of these is
statistically significant. These decreasing associations
with age occur despite the fact that conditional
prevalence of physical conditions among people with
MDE consistently increases with age in both developed
and developing countries. This increase is statistically
significant for 10 of 14 co-morbid conditions (the
exceptions being seasonal allergies, asthma, ulcers, and
headaches, for none of which is there a meaningful age
difference) in developed countries. In developing
countries, this increase is statistically significant for 9
of 14 co-morbid conditions (the exceptions being
stroke, seasonal allergies, asthma, chronic pains and
headaches).
AGE-RELATED DIFFERENCES IN
TREATMENT OF 12-MONTH MDE
Approximately half (54.3%) of respondents with
12-month MDE in developed countries and one-
quarter (25.2%) in developing countries reported
receiving some type of treatment for emotional
problems in the year before interview (Table 6). The
proportion that received treatment varies significantly
with age in developed countries (w23 ¼ 34:9, Po.001)
and is lowest in the oldest age group (44.0% vs.
48.4–61.7%). This pattern of under-treatment can be
seen in the youngest age group as well as in the oldest,
although the pattern in the oldest age group is more
pronounced than in the youngest age group when we
focus on the specialty sector.
DISCUSSION
The above results must be interpreted in the context
of several limitations: First, individuals with severe
physical or neurocognitive impairment may have been
less likely to participate, presumably reducing our
estimates of the associations between MDE and
physical conditions more among elderly than younger
respondents. Second, physical conditions were assessed
with a checklist, whereas mental disorders were
assessed with a comprehensive diagnostic interview.
This could have led to greater attenuation of estimated
associations involving physical than mental disorders.
It also reduced our ability to investigate specific
patterns of co-morbidity in the detail needed to
generate insights into the causal dynamics underlying
these associations. Future studies will need to use more
precise measures of physical disorders to address this
problem. Third, the fact that the assessments were
made with fully structured interviews rather than
clinical interviews might have artificially inflated
estimates of co-morbidity between diagnoses of MDE
and the other disorders due to overlap in core
symptoms (e.g., lethargy and insomnia), although we
tried to minimize this problem by not using organic
exclusion rules in making diagnoses of mental dis-
orders.
Notwithstanding these limitations, our results are
consistent with previous studies in showing that recent
MDE is less prevalent among older than younger
respondents in developed countries.[2,32] The finding
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that MDE generally does not decrease with age in
developing countries is also consistent with the small
number of previous studies that have examined this
pattern in developing countries;[33–36] although those
studies generally found depression to increase with age
whereas we found that association with age to be for
the most part insignificant. We did not investigate
reasons for the differing relationship between age and
depression between developed and developing coun-
tries, but this should be the focus of future study. Our
findings of higher mean MDE AOO and longer time
lag between AOO and current age with increasing age
are both substantively plausible and inconsistent with
evidence of age-related recall bias in previous epide-
miological surveys.[31] We attribute this difference
between the WMH results and the results of previous
survey to the use of an innovative AOO probing
technique in the WMH surveys that has been shown
experimentally to reduce recall bias.[37]
The finding that retrospectively reported number of
lifetime episodes increases with age among respondents
with a history of MDE is, like the finding for AOO,
substantively plausible. It is also consistent with
previous research.[3,8] The finding that age is positively
related to duration of 12-month depressive symptoms
among 12-month cases, in comparison, is inconsistent
with previous research that found no association
between age and 12-month duration of depressive
episodes.[39,40] It should be noted, though, that these
earlier studies were based on much smaller samples
than the WMH series. Our results regarding longer
episode duration among the oldest respondents are also
consistent across types of countries. We also found
consistently across countries that despite the longer
duration of recent episodes, recent MDE was reported
to cause less role impairment among older than
younger people. At least two previous studies also
found that symptom severity and severity of role
impairment due to 12-month depression are both
inversely related to age.[6,41] One plausible interpreta-
tion of the lower impact of depression on role
impairment with increasing age is that role demands
decrease with age. However, this interpretation does
not explain the finding that symptom severity also
decreases significantly with age in developing coun-
tries. Another possibility is that depression subtypes
change with age and that the subtypes more typical of
older people are less severe and impairing than those
more typical of younger people.[42,43] Although no
attempt was made here to examine depressive symptom
profiles by age to investigate this interpretation, this
would be a useful extension of the current results.
Our finding that 12-month prevalence of some
mental disorders decreases with age while prevalence
of most physical disorders increases with age is
consistent with much previous research.[13,14] We are
aware of little previous research, though, other than
earlier WMH analyses[15,44] on age differences in the
associations of depression with co-morbid disorders.
Our findings that these associations generally increase
with age when they involve co-morbid mental disorders
but decrease with age when they involve co-morbid
physical disorders are consequently of special interest.
The most plausible interpretation of the generally
increasing age-related ORs with other mental disorders
is that co-morbid cases have a more persistent course
TABLE 6. Past year treatment of emotional problems among respondent with 12-month DSM-IV/CIDI MDE by age
Age groups
All ages 18–34 35–49 50–64 651
% (se) % (se) % (se) % (se) % (se) Age difference w23
I. Developed
Specialty 29.3 (1.0) 28.4 (1.9) 34.2 (1.9) 28.8 (2.2) 14.0 (2.4) 29.3
General medical 36.0 (1.0) 29.1 (1.6) 41.2 (1.9) 41.7 (2.4) 36.7 (3.4) 19.7
Health care 50.4 (1.1) 44.6 (1.9) 57.6 (1.9) 54.0 (2.4) 41.6 (3.5) 32.7
Human services 7.3 (0.6) 5.5 (0.8) 9.8 (1.2) 8.2 (1.5) 3.9 (1.5) 8.6
CAMa 7.8 (0.7) 7.5 (1.2) 8.8 (1.2) 8.9 (1.5) 2.0 (0.9) 10.0
Any 54.3 (1.2) 48.4 (2.0) 61.7 (1.9) 58.3 (2.4) 44.0 (3.6) 34.9
(n) (2,973) (1,079) (990) (625) (279)
II. Developing
Specialty 12.6 (1.1) 13.6 (1.8) 14.2 (1.7) 10.4 (1.9) 2.8 (1.2) 3.6
General medical 10.8 (0.8) 8.6 (1.1) 12.2 (1.4) 13.2 (2.1) 13.8 (3.4) 1.7
Health care 20.7 (1.1) 18.1 (1.8) 24.6 (2.0) 22.4 (2.7) 15.7 (3.4) 4.6
Human services 4.3 (0.6) 4.0 (1.1) 4.5 (0.9) 4.5 (1.1) 5.0 (2.1) 0.4
CAMa 3.4 (0.5) 3.1 (0.7) 4.4 (1.0) 3.3 (1.2) 0.8 (0.5) 9.1
Any 25.2 (1.2) 22.1 (1.9) 29.4 (2.0) 28.0 (3.0) 21.0 (3.7) 5.5
(n) (2,244) (883) (721) (442) (198)
Significant age difference at the .05 level, two-sided test.
aComplementary-Alternative Medical (CAM) sector (e.g., herbalists, chiropractors, faith-healers, and self-help groups).
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than pure cases. Although it is beyond the scope of the
current report to investigate the reasons for such an
effect, it is noteworthy that this could also be impli-
cated in the longer duration of depressive episodes
among the elderly. The fact that the role impairment
associated with depression is lowest among the elderly
is all the more striking in light of the greater persis-
tence and higher co-morbidity of MDE with other
mental disorders among the elderly.
The generally decreasing age-related ORs of MDE
with physical disorders are more interpretable because
the age patterns in prevalence are different for MDE
(decreasing prevalence with age) and most physical
disorders (increasing prevalence with age). In a
situation of this sort, it is likely that the decreasing
ORs are at least partially attributable to a decrease in
the causal effects of physical disorders on MDE.
Whether or not causal effects of MDE on co-morbid
physical disorders also decrease with age is difficult to
say because the implications of such a decrease on the
prevalence of physical disorders would be negligible in
light of the much lower prevalence of MDE than
chronic physical conditions among the elderly. In
either case, though, the existence of these patterns
argue against the suggestion that the low prevalence of
MDE among the elderly in developed countries is due
to increased confounding of depression symptoms with
symptoms of chronic physical conditions.
Our results shed no light on why physical disorders
might have decreasing effects on MDE among the
elderly. One possibility proposed in the literature is
that elderly people are more accepting than those of
younger ages of the inevitability of physical illness,
resulting in the otherwise adverse psychological effects
of physical disorders being buffered.[6] A related
suggestion is that elderly people are ‘‘immunized’’
from the negative psychological effects of adversity by
prior life experience.[45] Although we are aware of no
direct test of these hypotheses, elderly people have
been shown to be more likely than younger people to
cope with adversity by using strategies that accept and
adapt rather than try to change their situations[46] and
that disengage from stressful situations in ways that
reduce adverse emotional effects.[47] Other research
has shown similar age differences in coping with
physical illness,[48] but has not investigated whether
these differences lead to reductions in the causal
effects of physical disorders on depression. Investiga-
tion of these buffering effects is an important next step
that, while beyond the scope of this study, might help
delineate positive patterns of response to the increas-
ing physical infirmity of advanced age. Another
possibility is that elderly people might have reduced
capacity to register or express mood states due to
autonomic, neuroendocrine, or cognitive dysfunction
that lead to reduced prevalence of mood disorders in
old age.[49] It is unclear, though, how this or any of the
other explanations proposed in the literature would
account for the fact that age-related decline in
depression prevalence is largely confined to developed
countries. New theorizing is required to explain this
specification.
CONCLUSION
We found that the widely documented decrease in
the prevalence of MDE among the elderly is much
more pronounced in developed than developing
countries. We found that even though the prevalence
of chronic physical conditions increased with age in
both developed and developing countries, the associa-
tion between depression and chronic conditions gen-
erally decreases with age. This result argues against the
view that the apparent decrease in clinical depression
among the elderly is due to increasing confounding of
the symptoms of depression with the symptoms of
chronic physical conditions. It is unclear why the age
gradient in depression differs in developed vs. devel-
oping countries, but this difference represents an
important and previously neglected specification that
provides an opportunity to investigate cross-national
differences in age-related correlates. Such an investiga-
tion might shed light on the reasons for the decline in
depression with age in developed countries. It is also
unclear why the associations between depression and
co-morbid physical conditions decrease with age
despite the prevalence of these conditions increasing
with age and the persistence of depression increasing
with age. An understanding of the causal processes
involved in this uncoupling of depression from physical
illness in old age could have important implications for
interventions with patients who have co-morbid
mental–physical disorders.
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